By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Neostem’s Suzhou Eyre receives Chinese Regulatory Approval For 6th Production Line
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Neostem’s Suzhou Eyre receives Chinese Regulatory Approval For 6th Production Line
Business

Neostem’s Suzhou Eyre receives Chinese Regulatory Approval For 6th Production Line

HerinaAyot
HerinaAyot
Share
4 Min Read
SHARE

NeoStem (AMEX:NBS) announced Monday that its subsidiary, Suzhou Eyre Pharmaceuticals, has received approval for its sixth production line from the Chinese State Food and Drug Administration (SFDA).

NeoStem (AMEX:NBS) announced Monday that its subsidiary, Suzhou Eyre Pharmaceuticals, has received approval for its sixth production line from the Chinese State Food and Drug Administration (SFDA).

NeoStem, a pharmaceutical company that focuses on stem cell-based technologies, acquired a 51% interest in China-based Suzhou Eyre, which manufactures and develops generic antibiotics and anti-infective drugs, from China Biopharmaceutical Holdings in October 2009.

The sixth line of production, of which there are two more awaiting approval, will push Suzhou Eyre’s product count to nearly 200 drugs. The line is responsible for 20 finished pharmaceutical products, 80% of which are on the China National Insurance Drug List.

More Read

Electron Micrograph of HCV
Is Hepatitis C Treatment Cost-Effective?
Physicians Are Your Top Brand Ambassadors!
Building a Brand Journalism Team: Michael Yoder [PODCAST]
Digital Marketing For Healthcare: What You Need To Know
Adapting to Millennials with Health Care Technology

The company’s production lines provided 99% of its $70 million sales in 2010. Its first quarter sales for this year totaled $18 million, a 15% year-over-year increase.

“The Chinese pharmaceutical market, which is the third largest in the world, has estimated sales of over $50 billion for 2011, and is expected to double in the next five years,” said NeoStem CEO Dr. Robin Smith.

According to recent analyst reports, NeoStem, with the assistance of Suzhou Eyre, could see a revenue growth rate of 20% between 2011 and 2013, with the potential to reach $119 million in pharmaceutical sales by 2013.

Indeed, Suzhou Eyre is also in the midst of re-locating to its new 53,000 square foot facility, which it expects will loosen its capacity constraints, improve its productivity and double its capacity.

“Based on the capacity of the new facility, and anticipated volume growth, Erye’s top line revenues should see solid growth in the years ahead and NeoStem’s management will consider our multiple options to realizing the benefits of this increasingly valuable asset,” Smith added.

Aside from its Chinese pharma business, New York-based Neostem has gradually expanded its operations since starting out as a provider of adult stem cell collection and storage services, branching out into cell therapeutics, which is focused on using stem cells to help cure disease.

In January, the company acquired Progenitor, which has cell therapy manufacturing facilities, as well as processing and storage facilities for stem cells collected from the umbilical cord at birth, located on the east and west coast of the US.

Progenitor has performed over 30,000 cell therapy procedures and has processed and stored over 18,000 cell therapy products.

As a result of the acquisition, NeoStem can also now develop stem cell therapies in-house, placing it in a solid position for future growth in the field.

With positive results coming out of China today, NeoStem’s stock jumped almost 5% on the AMEX on Monday, trading at $1.47 per share. –Olivia D’Orazio

Source

 

TAGGED:chinahealthcare business
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

Kiosk Offers Health Assessment

March 23, 2011

Are Electronic Medical Records Really Causing a Crisis?

October 30, 2014

Reducing Surgical Complications: How to Make it Happen Faster

December 4, 2012

Twelve “Connected Health” Innovators Are Staying Out Front

January 27, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?